Discover
KYTX
Kyverna Therapeutics, Inc.
8.44
2 x 6.40
2 x 10.80
bid
ask
-
0.47
5.27%
2 @ 04:00 PM
8.77 +0.33 (3.91%)
| Ytd | -10.21% | |
| 1y | 204.69% |
8.37
day range
8.97
2.52
52 week range
13.67
| Open | 8.90 | Prev Close | 8.91 | Low | 8.37 | High | 8.97 | Mkt Cap | 513.11M |
| Vol | 805.98K | Avg Vol | 1.09M | EPS | -3.27 | P/E | N/A | Forward P/E | -1.00 |
| Beta | N/A | Short Ratio | 7.35 | Inst. Own | 76.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 8.72 | 200-d Avg | 8.04 | 1yr Est | 27.33 |
| Income Statement | |||
| Operating Expenses | 41.37M | ||
| Research and Development Expense | 30.07M | ||
| Selling, General and Administrative Expense | 11.29M | ||
| Operating Income | -41.37M | ||
| Interest Expense | 667.00K | ||
| Net Income | -39.73M | ||
| Net Income Common Stock | -39.73M | ||
| Net Income Common Stock (USD) | -39.73M | ||
| Consolidated Income | -39.73M | ||
| Earnings per Basic Share | -0.66 | ||
| Earnings per Basic Share (USD) | -0.66 | ||
| Earnings per Diluted Share | -0.66 | ||
| Earning Before Interest & Taxes (EBIT) | -39.06M | ||
| Earning Before Interest & Taxes (USD) | -39.06M | ||
| Weighted Average Shares | 60.43M | ||
| Weighted Average Shares Diluted | 60.43M | ||
| Balance Sheet | |||
| Cash and Equivalents | 32.74M | ||
| Cash and Equivalents (USD) | 32.74M | ||
| Investments | 204.25M | ||
| Investments Current | 204.25M | ||
| Current Assets | 241.73M | ||
| Property, Plant & Equipment Net | 9.73M | ||
| Total Assets | 257.02M | ||
| Debt Current | 1.99M | ||
| Total Debt | 33.76M | ||
| Current Liabilities | 29.67M | ||
| Debt Non-Current | 31.77M | ||
| Total Liabilities | 61.44M | ||
| Accumulated Retained Earnings (Deficit) | -464.55M | ||
| Accumulated Other Comprehensive Income | -96.00K | ||
| Shareholders Equity | 195.58M | ||
| Shareholders Equity (USD) | 195.58M | ||
| Assets Non-Current | 15.30M | ||
| Total Debt (USD) | 33.76M | ||
| Liabilities Non-Current | 31.77M | ||
| Trade and Non-Trade Payables | 11.60M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 970.00K | ||
| Net Cash Flow from Financing | -101.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -91.90M | ||
| Issuance (Purchase) of Equity Shares | 243.00K | ||
| Issuance (Repayment) of Debt Securities | -86.00K | ||
| Net Cash Flow from Investing | -50.20M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -50.20M | ||
| Net Cash Flow from Operations | -41.60M | ||
| Share Based Compensation | 3.17M | ||